is set to surge higher even after its epic 220% rally so far this year, according to Jefferies.
The bullish rating hinges on Moderna's COVID-19 vaccine working and resulting in large government supply contracts, Jefferies equity analyst Michael Yee wrote in a Monday note. In the first full year of sales of its potential vaccine, Jefferies' model shows it could bring in $2 billion worldwide if roughly 50 million people get the vaccine at $50. This could grow to a peak of $5 billion between 2025 and 2026, according to the note.
English press release of Dr. Zelenko new study. Please share. Treat early and live. Combo works.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
ICU head in Bergamo, Italy, says COVID-19 causing 'chronic damage' - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Weiterlesen »